Ligand Pharmaceuticals pharma partners with the signing of global license and supply agreements with Spectrum Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan.
Under the terms of the license agreement, Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestone payments.
Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan.
The Captisol-enabled melphalan program is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Spectrum, a big biotech company, will immediately assume all development of the program as a result of this license.
For further deal information visit Current Agreements (subscription required
Report: Practical Guide to Finding Partners
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value